Article: PURE PROTEIN L.L.C. DEBUTS POLYTEST BINDING ASSAY.

Emergent Technologies Inc. (ETI), has announced that its portfolio company, Pure Protein L.L.C., has commercialized an accurate and sensitive assay for peptides binding to HLA molecules based on soluble HLA proteins and fluorescent peptide standards.

This assay, called PolyTest, allows vaccine designers to quickly assess how well a target is displayed to the immune system and to determine for which segment of the population the vaccine will be protective.

HLA proteins present pieces of protein from germs and cancer cells to the white blood cells of the immune system. Pure Protein's core technology is its ability to produce large quantities of soluble HLA ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!